Top Markets
#1 Pleasing Gold Pleasing Gold +562.02%
#2 Islamic Coin Islamic Coin +154.23%
#3 PulseChain PulseChain +52.83%
#4 BOOK OF MEME BOOK OF MEME +49.57%
#5 DogBull DogBull +38.73%
#6 Nockchain Nockchain +25.73%
#7 ORDI ORDI +21.49%
#8 PondCoin PondCoin +21.01%
#9 rsERG rsERG +18.16%
#10 Monad Monad +17.83%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM
Rank in Stocks #27177
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.
Share Price
$1.10
Last synced: 2026-08-19
Market Cap
$34.64M
Change (1 day)
4.16%
Change (1 year)
-32.68%
Country
US
Trade Actinium Pharmaceuticals, Inc. (ATNM)

Category

Healthcare
Number of shares outstanding for Actinium Pharmaceuticals, Inc. (ATNM)
Number of shares outstanding as of August 2026: 0
According to Actinium Pharmaceuticals, Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Actinium Pharmaceuticals, Inc. (ATNM) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH